CN102416034B - Medicament for treating myocardial ischemia in coronary heart disease and application thereof - Google Patents
Medicament for treating myocardial ischemia in coronary heart disease and application thereof Download PDFInfo
- Publication number
- CN102416034B CN102416034B CN2011104070974A CN201110407097A CN102416034B CN 102416034 B CN102416034 B CN 102416034B CN 2011104070974 A CN2011104070974 A CN 2011104070974A CN 201110407097 A CN201110407097 A CN 201110407097A CN 102416034 B CN102416034 B CN 102416034B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- heart disease
- coronary heart
- myocardial ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a medicament for treating myocardial ischemia in coronary heart disease. The medicament is prepared from the following raw material medicaments in parts by weight: 20-40 parts of astragalus root, 2-4 parts of buthus martensi kirsch, 4-8 parts of centipede, 10-20 parts of bitter orange, 30-60 parts of root of red-rooted salvia and 9-15 parts of peach kernel. The invention also relates to application of the medicament to preparation of medicaments for preparing the coronary heart disease, particularly aiming at the myocardial ischemia in coronary heart disease stenting. The medicament is prepared from pure traditional Chinese medicines, has an obvious curative effect for treating the coronary heart disease from symptoms and mechanism, and has the advantages of wide medicament symptomatic range, no toxic or side effect, less raw material components, rich raw materials, low cost, simple preparation process and suitability for promotion and application.
Description
Technical field
The present invention relates to a kind of medicine and application thereof for the treatment of coronary heart disease and myocardial ischemia, specifically, is to be the Chinese patent medicine of feedstock production with the Chinese herbal medicine.
Background technology
Coronary heart disease is one of most commonly encountered diseases, frequently-occurring disease clinically, it is a kind of myocardial ischemia-anoxemia (angina pectoris) that is caused by coronary artery organic (atherosclerosis or dynamic property vasospasm) stenosis or occlusion or the heart disease of myocardial necrosis (myocardial infarction), also claims ischemic heart desease.Our the coronary heart disease majority said is that tremulous pulse organic stenosis or obstruction cause myocardial ischemia-anoxemia to cause at ordinary times, and the shape atherosclerotic heart disease wins again.Due to its coronary stricture polyphyly fatty material was piled up along blood vessel, this process was called arteriosclerosis.Arteriosclerosis develops into to a certain degree, and coronary stricture increases the weight of gradually, and restriction flows into the blood flow of cardiac muscle.Heart can not get enough oxygen and supplies with, and the chest discomfort will take place, i.e. angina pectoris.This disease cause of disease is unclear fully as yet so far, but thinks that lowly to reach factor such as older relevant with hypertension, hyperlipemia, high blood viscosity, diabetes, endocrine function, and its sickness rate is growth trend year by year.
At the treatment of coronary heart disease, main principle is to improve blood supply coronarius and alleviate myocardial ischemia and oxygen consumption, treatment and the atherosis development of prevention of arterial simultaneously.Wherein, the coronary heart disease stenting is one of therapeutic method of surgery of coronary heart disease, its ultimate principle is that foley's tube is inserted in the narrow blood vessel by vascular puncture, external sacculus is added compression swelling, strut narrow blood vessel wall, make lesion vessels recover unimpeded, 1-2 place coronary stricture and put support and can select interventional therapy easily.But find clinically, some coronary heart disease coronary artery bracket postoperative patients are the problem of coronary stricture, myocardial ischemia still, for this class patient, increase coronary arterial tree or collateral circulation, the confession of recovery ischemic myocardium blood, also be very important to improving patient's symptom and prognosis.
Chinese patent literature CN 01131203.3, October 15 2003 day for announcing, a kind for the treatment of coronary heart disease and angina pectoris compositions for the treatment of is disclosed, the raw material of described pharmaceutical composition comprises Radix Ginseng 3-10 gram, Hirudo 3-11 gram, Eupolyphaga Seu Steleophaga 5-10 gram, Olibanum (processed) 1-5 gram, Radix Paeoniae Rubra 3-9 gram, Lignum Dalbergiae Odoriferae 1-5 gram, Lignum Santali Albi 1-5 gram, Scorpio 3-9 gram, Periostracum Cicadae 3-12 gram, Scolopendra 1-3 gram, Borneolum Syntheticum 1-7 gram, Semen Ziziphi Spinosae (parched) 3-10 gram, this medicine can improve degree of myocardial ischemia, removing obstruction in the collateral to relieve pain; Chinese patent literature CN 200610003904.5, June 25 2008 day for announcing, a kind of medicine for the treatment of coronary heart disease is disclosed, described medicine is to be made by following weight portion crude drug: Radix Notoginseng 65-100 part, Radix Ginseng 58-100 part, Radix Astragali 80-100 part, succinum 70-100 part, Oletum Trogopterori 75-100 part, Ganoderma 68-100 part, Rhizoma Chuanxiong 75-100 part, Radix Ophiopogonis 76-100 part, Placenta Hominis 40-60 part, piece of antler 20-50 part, roasted SQUAMA MANITIS into puffy with sand 25-50 part, Resina Draconis 30-50 part, unprocessed leech 28-50 part, clear Scorpio 25-50 part, Scolopendra 68-100 part, Pheretima 28-50 part, this medicine cures mainly coronary heart disease.But raw material type is various on the one hand for these medicines, be subjected to the wide rare restriction in raw material source unavoidably, and because some Chinese crude drug is expensive, can bring heavy financial burden to the patient, be not suitable for promoting the use of, on the other hand, the specific aim for the treatment of coronary heart disease and myocardial ischemia is not strong or effect is not remarkable, therefore, need the medicine that a kind of component is few, treatment coronary heart disease and myocardial ischemia effect is remarkable, raw material is easy to get badly.And yet there are no report about this class medicine at present.
Summary of the invention
The objective of the invention is at deficiency of the prior art, a kind of medicine for the treatment of coronary heart disease and myocardial ischemia is provided.
One purpose more of the present invention is that a kind of purposes for the treatment of the medicine of coronary heart disease and myocardial ischemia is provided.
For achieving the above object, the technical scheme taked of the present invention is:
A kind of medicine for the treatment of coronary heart disease and myocardial ischemia, described medicine are to be made by following bulk drugs: Radix Astragali 20-40 part, Scorpio 2-4 part, Scolopendra 4-8 part.
If described drug main is made by following bulk drugs: 30 parts of the Radixs Astragali, 3 parts of Scorpios, 6 parts of Scolopendras.
Described medicine also comprises following bulk drugs: Fructus Aurantii 10-20 part.
Described medicine also comprises following bulk drugs: 15 parts of Fructus Aurantiis.
Described medicine also comprises following bulk drugs: Radix Salviae Miltiorrhizae 30-60 part, Semen Persicae 9-15 part.
Described medicine also comprises following bulk drugs: 45 parts of Radix Salviae Miltiorrhizaes, 12 parts in Semen Persicae.
The medicament of described medicine is capsule, powder, tablet, oral liquid or injection.
For realizing above-mentioned second purpose, the technical scheme that the present invention takes is:
The application of described medicine in preparation treatment coronary heart disease and myocardial ischemia medicine.
Described coronary heart disease and myocardial ischemia is myocardial ischemia behind the coronary heart disease stenting.
The application of described medicine in preparation increase collateral circulation and/or angiogenesis promoting medicine.
The invention has the advantages that:
1, medicine of the present invention is started with from disease mechanism, the Radix Astragali is monarch's replenishing qi and promoting blood flow, the ministerial drug Scorpio, Scolopendra activating blood circulation to dissipate blood stasis collateral dredging, assistant is with the Semen Persicae blood circulation promoting and blood stasis dispelling, Fructus Aurantii vital energy regualting and blood circulation-promoting, Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, tranquilizing by nourishing the heart, all medicines share plays benefiting QI for activating blood circulation altogether, regulating qi and dredging collateral, the effect of tranquilizing by nourishing the heart, on the pharmacology, these Chinese medicines have coronary artery dilating, antiplatelet aggregation, antithrombotic forms, and reduces blood viscosity, improves microcirculation, the Radix Astragali, Radix Salviae Miltiorrhizae has more and improves the circulation endothelium progenitor cell function, angiogenesis promoting and endothelium repair function, treatment coronary heart disease and myocardial ischemia short treating period, effect is remarkable.
2, medicine of the present invention is made by pure Chinese medicine, the medicine wide ranges of suiting the medicine to the illness, no side effects.
3, medicine material component of the present invention is few, and abundant raw materials is easy to get, low price, and preparation technology is simple, is fit to promote the use of.
The specific embodiment
Below the specific embodiment provided by the invention is elaborated.
Embodiment 1
The oral liquid preparation (one) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 4 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 2
The oral liquid preparation (two) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 8 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 3
The oral liquid preparation (three) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 4
The oral liquid preparation (four) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 5
The oral liquid preparation (five) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 6
The oral liquid preparation (six) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 7
The oral liquid preparation (seven) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 30 parts of Chinese medicine astragalus, 3 parts of Scorpios, 6 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 8
The oral liquid preparation (eight) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 25 parts of Chinese medicine astragalus, 3 parts of Scorpios, 7 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 9
The oral liquid preparation (nine) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 35 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 10
The oral liquid preparation (ten) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 25 parts of Chinese medicine astragalus, 2 parts of Scorpios, 7 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 11
The oral liquid preparation (11) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 6 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 12
The oral liquid preparation (12) for the treatment of coronary heart disease and myocardial ischemia medicine one
Get 30 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 13
The oral liquid preparation (one) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 4 parts of Scolopendras, 10 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 14
The oral liquid preparation (two) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 8 parts of Scolopendras, 20 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 15
The oral liquid preparation (three) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, 20 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 16
The oral liquid preparation (four) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, 10 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 17
The oral liquid preparation (five) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, 10 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 18
The oral liquid preparation (six) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, 20 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 19
The oral liquid preparation (seven) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 30 parts of Chinese medicine astragalus, 3 parts of Scorpios, 6 parts of Scolopendras, 15 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 20
The oral liquid preparation (eight) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 25 parts of Chinese medicine astragalus, 3 parts of Scorpios, 7 parts of Scolopendras, 15 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 21
The oral liquid preparation (nine) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 35 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 18 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 22
The oral liquid preparation (ten) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 25 parts of Chinese medicine astragalus, 2 parts of Scorpios, 7 parts of Scolopendras, 12 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 23
The oral liquid preparation (11) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 6 parts of Scolopendras, 12 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 24
The oral liquid preparation (12) for the treatment of coronary heart disease and myocardial ischemia medicine two
Get 30 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 18 parts of Fructus Aurantiis, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 25
The oral liquid preparation (one) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 4 parts of Scolopendras, 10 parts of Fructus Aurantiis, 60 parts of Radix Salviae Miltiorrhizaes, 15 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 26
The oral liquid preparation (two) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 8 parts of Scolopendras, 20 parts of Fructus Aurantiis, 30 parts of Radix Salviae Miltiorrhizaes, 9 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 27
The oral liquid preparation (three) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, 20 parts of Fructus Aurantiis, 60 parts of Radix Salviae Miltiorrhizaes, 15 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 28
The oral liquid preparation (four) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, 10 parts of Fructus Aurantiis, 60 parts of Radix Salviae Miltiorrhizaes, 9 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 29
The oral liquid preparation (five) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, 10 parts of Fructus Aurantiis, 30 parts of Radix Salviae Miltiorrhizaes, 15 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 30
The oral liquid preparation (six) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, 20 parts of Fructus Aurantiis, 30 parts of Radix Salviae Miltiorrhizaes, 15 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 31
The oral liquid preparation (seven) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 30 parts of Chinese medicine astragalus, 3 parts of Scorpios, 6 parts of Scolopendras, 15 parts of Fructus Aurantiis, 45 parts of Radix Salviae Miltiorrhizaes, 12 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 32
The oral liquid preparation (eight) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 25 parts of Chinese medicine astragalus, 3 parts of Scorpios, 7 parts of Scolopendras, 15 parts of Fructus Aurantiis, 60 parts of Radix Salviae Miltiorrhizaes, 11 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 33
The oral liquid preparation (nine) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 35 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 18 parts of Fructus Aurantiis, 50 parts of Radix Salviae Miltiorrhizaes, 13 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 34
The oral liquid preparation (ten) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 25 parts of Chinese medicine astragalus, 2 parts of Scorpios, 7 parts of Scolopendras, 12 parts of Fructus Aurantiis, 40 parts of Radix Salviae Miltiorrhizaes, 12 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 35
The oral liquid preparation (11) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 6 parts of Scolopendras, 12 parts of Fructus Aurantiis, 60 parts of Radix Salviae Miltiorrhizaes, 9 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 36
The oral liquid preparation (12) for the treatment of coronary heart disease and myocardial ischemia medicine three
Get 30 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 18 parts of Fructus Aurantiis, 40 parts of Radix Salviae Miltiorrhizaes, 10 parts in Semen Persicae, put in the decoction container, add the water logging bubble 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
Embodiment 37
The preparation for the treatment of coronary heart disease and myocardial ischemia medicinal tablet/capsule
Get the arbitrary described medicine of embodiment 1-36, add 5-8 times of water gaging, decocted 4 hours, leach medicine juice.Add 6-10 times of water gaging again, decocted 2-3 hour, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 3 times of amounts of concentrated solution ethanol, stirs precipitation and spends the night.Get supernatant, be concentrated into thick extractum; Add pharmaceutical aids, vacuum drying is pulverized and is granulated, and is pressed into tablet or fills encapsulated.
Embodiment 38
The preparation for the treatment of coronary heart disease and myocardial ischemia drug particles
Get the arbitrary described medicine of embodiment 1-36, add 8 times of water gagings, decocted 3 hours, leach medicine juice.Add 8 times of water gagings again, decocted 1 hour, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 2 times of amounts of concentrated solution ethanol, stirs precipitation and spends the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, granulate, drying, granulate gets the 20g granule, packing 10g/ bag.
Embodiment 39
The preparation for the treatment of coronary heart disease and myocardial ischemia drug mixture/syrup
Get the arbitrary described medicine of embodiment 1-36, add 12 times of water gagings, decocted 3-4 hour, leach medicine juice.Add 8 times of water gagings again, decocted 3 hours, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 3 times of amounts of concentrated solution ethanol, stirs precipitation and spends the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, make mixture or syrup.
Embodiment 40
The randomized controlled trial of myocardial ischemia behind the pharmaceutical intervention coronary heart disease stenting of the present invention
1 clinical data and method
1.1 case is selected and grouping
All case derives from June, 2004 to the 2006 intracardiac patient of section in year JIUYUE Shanghai Chinese Medicine Hospital.Selected 121 routine patients with coronary heart disease mostly are acute myocardial infarction and angina pectoris altogether.Male's 66 examples wherein, women's 55 examples, age 35-75 year, average (67 ± 6) year, be divided into treatment group 1, treatment group 2, treatment group 3 and matched group by selected standard completely random method.Include standard in: the equal underwent coronary radiography of patient is made a definite diagnosis coronary heart disease, and in age 35-75 year, male or female meets following: 1. belong to acute scheming infarction or stable angina pectoris or unstable angina pectoris.2. there are two or narrow or inaccessible more than two main coronary artery arteries and veins 60%-99% through coronary angiography, have at least one to be fit to row coronary artery bracket implantation, and owing to also have an arteria coronaria blood vessel still to exist 〉=narrow or inaccessible more than 75% behind a variety of causes Stent at least.3. the lesion vessels diameter is 2.5-4.0mm, and does not go coronary artery balloon dilatation (PTCA) in the past.4. implanting coronary artery bracket is non-bracket for eluting medicament, and stent length is not more than 25mm.5. there are not aspirin, heparin, Bo Liwei taboo person.Exclusion standard: 1. be associated with diabetes.2. severe cardiac functional defect, cardiac function is IV person.3. long pathological changes is greater than 25mm person.4. acute upper respiratory tract infection.5. malignant change.6. bifurcated lesions person.7. coronary artery bypass (CABG) person.
1.2 Therapeutic Method
Four groups of patients all use fat regulation medicine according to the state of an illness, anticoagulant, and the platelet receptor blocker, nitrate esters, beta-Blocking agent, the calcium ion blocker, ACEI, medicines such as ARB etc. are as Primary Care.Treatment group 1, treatment group 2 and treatment group 3 respectively behind Stent 24h internal therapy group give the medicine of embodiment 7, embodiment 17 and embodiment 34 described treatment coronary heart disease, a 150ml, every day three times, oral.Matched group only adopts Primary Care.Cycle is 6 months.
1.3 observation index and method
1.3.1 arteria coronaria side shoot integration
Adopt blood vessel numeral inspection shadow (DSA) to detect the degree of arteria coronaria collateral circulation, the arteria coronaria side shoot is according to international Cohen-Rentrop method method (Isaac Pouriati, MD, Carey Kimmelstiel, MD, William Rand, PhD.Statin use isassociated with enhanced collateralizaton of severely diseased coronary arteries. America heart journal, November 2003 Volume146, Number5.876-81.).0=is without any collateral blood vessels, and 1=has collateral blood vessels to be poured but do not arrive the visceral pericardium part, and the 2=collateral blood vessels partly is filled into visceral pericardium, and the 3=collateral blood vessels is filled into visceral pericardium fully.Then point out higher integration if any a plurality of side shoots, then select a higher blood vessel of integration to calculate if any vascular lesion many places, many places side shoot.
1.3.2 stent restenosis
According to the standard shadowgraph technique respectively before PTCA, support implants the back, row coronary angiography after six months, measures the lumen of vessels internal diameter respectively behind the injection nitroglycerin in arteria coronaria.
1.3.3 ejection fraction (EF)
Use the two dimensional echocardiogram machine to adopt and revise Simpson formula measurement EF.
1.4 date processing
Adopt SPSS 11.0 statistical softwares statistics, carry out the variance analysis of repeated measure, t check and χ
2Check.With P＜0.05 for statistical significance is arranged.
2 results
The variation of four groups for the treatment of front and back arteria coronaria collateral circulation integrations is as shown in table 1, as can be seen from Table 1, four groups all have less collateral circulation even do not have collateral circulation when selected, but treatment group 1, treatment group 2 and treatment group 3 are after through 6 months treatment, more side shoot has appearred, P＜0.01 is compared with matched group and to be had utmost point significant difference.
The variation of arteria coronaria collateral circulation integration before and after four groups of treatments of table 1
| Handle | n | Before the treatment | 6 months |
| Treatment group 1 | 30 | 0.12±0.1 | 2.05±0.1**## |
| Treatment group 2 | 30 | 0.13±0.11 | 2.08±0.12**## |
| Treatment group 3 | 30 | 0.12±0.12 | 2.12±0.11**## |
| Matched group | 31 | 0.13±0.12 | 1.40±0.11 |
Annotate: compare with matched group: * * P＜0.01; When selected relatively: ##P＜0.01.
Four groups of variations for the treatment of front and back tube chamber and stent restenosis are as shown in table 2, and as can be seen from Table 2, aspect minimum lumen diameter and luminal stenosis percentage rate, treatment group 1, treatment group 2, treatment group 3 and matched group be no difference of science of statistics relatively all.Total clinical restenosis rate is 11%, and wherein treatment group 1 has 3 examples, and treatment group 2 has 3 examples, and treatment group 3 has 2 examples, and matched group has 3 examples.
The variation of tube chamber and stent restenosis before and after four groups of treatments of table 2
| ? | Treatment group 1 | Treatment group 2 | Treatment group 3 | Matched group |
| ? | n=30 | n=30 | n=30 | n=31 |
| Minimum lumen diameter (mm) | ? | ? | ? | ? |
| Before the angioplasty | 1.12±0.41 | 1.13±0.35 | 1.12±0.39 | 1.13±0.48 |
| After support is implanted at once | 3.08±0.61 | 3.02±0.55 | 2.98±0.56 | 2.99±0.47 |
| After 6 months | 1.99±0.74 | 1.98±0.62 | 1.99±0.60 | 2.09±0.59 |
| With reference to lumen diameter (mm) | ? | ? | ? | ? |
| Before the angioplasty | 2.93±0.45 | 2.93±0.44 | 2.93±0.47 | 2.93±0.46 |
| After support is implanted at once | 3.29±0.50 | 3.28±0.54 | 3.29±0.51 | 3.23±0.49 |
| After 6 months | 2.96±0.44 | 2.97±0.34 | 2.97±0.45 | 2.78±0.43 |
| Luminal stenosis percentage rate (%) | ? | ? | ? | ? |
| Before the angioplasty | 61±15 | 60±14 | 61±13 | 60±14 |
| After support is implanted at once | 8±9 | 9±9 | 8±9 | 7±8 |
| After 6 months | 33±19 | 32±18 | 34±19 | 27±16 |
| Clinical restenosis incidence rate (%) | 3 | 3 | 2 | 3 |
Annotate: compare with matched group: * P＜0.05.
The variation of four groups for the treatment of front and back EF is as shown in table 3, as can be seen from Table 3, treatment group 1, treatment group 2 and treatment group 3 are after 6 months, and ejection fraction obviously improves, treatment group 1, treatment group 2, treatment group 3 and matched group and relatively preceding with treatment, P＜0.05 has remarkable significant difference.
The variation of EF before and after four groups of treatments of table 3
| Handle | n | Before the treatment | 6 months |
| Treatment group 1 | 30 | 0.46±0.24 | 0.51±0.22*# |
| Treatment group 2 | 30 | 0.46±0.20 | 0.51±0.26*# |
| Treatment group 3 | 30 | 0.45±0.19 | 0.52±0.27*# |
| Matched group | 31 | 0.45±0.21 | 0.44±0.22 |
Annotate: compare with matched group: * P＜0.05; When selected relatively: #P＜0.05.
The GCP principle is followed in this research strictness, carries out contrived experiment according to completely random, contrast, single blind method for designing.Under study for action routine blood test, routine urinalysis, hepatic and renal function etc. are observed the safety of medicine of the present invention, the result does not have untoward reaction to take place, and has at first proved the safety of this medicine.Secondly, result of study confirms that medicine of the present invention can significantly improve collateral circulation and the ejection fraction of patients with coronary heart disease, and then improves myocardial ischemia, significantly improves cardiac function.
In the medicine of the present invention, the Radix Astragali is monarch's replenishing qi and promoting blood flow; Ministerial drug Scorpio, Scolopendra activating blood circulation to dissipate blood stasis collateral dredging; Assistant is with the Semen Persicae blood circulation promoting and blood stasis dispelling, Fructus Aurantii vital energy regualting and blood circulation-promoting, Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, tranquilizing by nourishing the heart.All medicines share the effect of playing benefiting QI for activating blood circulation, regulating qi and dredging collateral, tranquilizing by nourishing the heart altogether.The viewpoint that meets " promoting blood circulation to remove obstruction in the collateral, QI invigorating activate yang to discuss and control coronary heart disease " of the proposition of clinical practice for many years.Simultaneously, modern pharmacological research also confirms: these Chinese medicines have coronary artery dilating, antiplatelet aggregation, and antithrombotic forms, and reduces blood viscosity, improves microcirculation; The Radix Astragali, Radix Salviae Miltiorrhizae have more and improve the circulation endothelium progenitor cell function, angiogenesis promoting and endothelium repair function.The possible mechanism that can increase collateral circulation, short angiogenesis about this invention medicine is: 1) anticoagulant, the antithrombotic that has owing to Chinese medicine, blood vessel dilating improves microcirculatory effect, directly impels the opening of the collateral circulation that has existed.2) zoopery before confirms, Chinese medicine can obviously raise the heart infarction rat VEGF, the expression of basic fibroblast growth factor and mRNA promotes the ischemic myocardium angiogenesis, this is because the characteristic of VEGF: the one, and can significantly mobilize endothelial progenitor cells to move to the blood circulation from bone marrow, increase the quantity of EPC, impel angiogenesis; The 2nd, move the recovery that endothelium is accelerated in breeding by stimulating endothelial cell; The 3rd, induce the nitric oxide and the prostacyclin secretion that suppress proliferation of smooth muscle and platelet aggregation.So medicine of the present invention may be bunch to make angiogenesis by above-mentioned approach.
The above only is preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.
Claims (2)
1. a medicine for the treatment of coronary heart disease and myocardial ischemia is characterized in that, described medicine is to be made by following bulk drugs: Radix Astragali 20-40 part, Scorpio 2-4 part, Scolopendra 4-8 part.
2. medicine according to claim 1 is characterized in that, described medicine is to be made by following bulk drugs: 30 parts of the Radixs Astragali, 3 parts of Scorpios, 6 parts of Scolopendras.
3. medicine according to claim 1 is characterized in that, described medicine also comprises following bulk drugs: Fructus Aurantii 10-20 part.
4. medicine according to claim 1 and 2 is characterized in that, described medicine also comprises following bulk drugs: 15 parts of Fructus Aurantiis.
5. medicine according to claim 3 is characterized in that, described medicine also comprises following bulk drugs: Radix Salviae Miltiorrhizae 30-60 part, Semen Persicae 9-15 part.
6. medicine according to claim 3 is characterized in that, described medicine also comprises following bulk drugs: 45 parts of Radix Salviae Miltiorrhizaes, 12 parts in Semen Persicae.
7. according to claim 1,3 or 5 described medicines, it is characterized in that the medicament of described medicine is capsule, granule, tablet, oral liquid, mixture or syrup.
8. according to claim 1,3 or 5 described medicines, it is characterized in that the application of described medicine in preparation treatment coronary heart disease and myocardial ischemia medicine.
9. application according to claim 8 is characterized in that, described coronary heart disease and myocardial ischemia is myocardial ischemia behind the coronary heart disease stenting.
10. according to claim 1,3 or 5 described medicines, it is characterized in that the application of described medicine in preparation increase collateral circulation and/or angiogenesis promoting medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104070974A CN102416034B (en) | 2011-12-09 | 2011-12-09 | Medicament for treating myocardial ischemia in coronary heart disease and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104070974A CN102416034B (en) | 2011-12-09 | 2011-12-09 | Medicament for treating myocardial ischemia in coronary heart disease and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102416034A CN102416034A (en) | 2012-04-18 |
| CN102416034B true CN102416034B (en) | 2013-07-03 |
Family
ID=45940836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104070974A Expired - Fee Related CN102416034B (en) | 2011-12-09 | 2011-12-09 | Medicament for treating myocardial ischemia in coronary heart disease and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102416034B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481494A (en) * | 2018-12-25 | 2019-03-19 | 辽宁中医药大学 | A kind of compound traditional Chinese medicine composite and animal experiment method preventing and treating coronary microcirculation dysfunction |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1579519A (en) * | 2004-05-21 | 2005-02-16 | 周九北 | Traditional Chinese medicine for treating headache disease |
-
2011
- 2011-12-09 CN CN2011104070974A patent/CN102416034B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1579519A (en) * | 2004-05-21 | 2005-02-16 | 周九北 | Traditional Chinese medicine for treating headache disease |
Non-Patent Citations (6)
| Title |
|---|
| 中药保护心肌缺血损伤的非循环机制研究进展;谷万里等;《中西医结合心脑血管病杂志》;20050530(第05期);422-426 * |
| 枳壳煮散治疗冠心病心绞痛;黄秀玲等;《山东中医杂志》;19990820(第08期);357 * |
| 桃仁提取物抗大鼠心肌缺血作用的研究;耿涛等;《苏州大学学报(医学版)》;20050325(第02期);238-239 * |
| 耿涛等.桃仁提取物抗大鼠心肌缺血作用的研究.《苏州大学学报(医学版)》.2005,(第02期), |
| 谷万里等.中药保护心肌缺血损伤的非循环机制研究进展.《中西医结合心脑血管病杂志》.2005,(第05期), |
| 黄秀玲等.枳壳煮散治疗冠心病心绞痛.《山东中医杂志》.1999,(第08期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102416034A (en) | 2012-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103816280B (en) | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition | |
| CN101524469A (en) | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof | |
| CN101524470B (en) | Traditional Chinese medicine preparation for curing angiocardiopathy stent restenosis and preparation method thereof | |
| CN101647856B (en) | Medicine for treating coronary heart disease and preparation method thereof | |
| CN102416034B (en) | Medicament for treating myocardial ischemia in coronary heart disease and application thereof | |
| CN100490843C (en) | Prince's-feather preparation and its preparation process and application | |
| CN100536900C (en) | Traditional Chinese medicinal composition for treating coronary disease and its preparation method | |
| CN103505612A (en) | Traditional Chinese medicine composition containing total flavonoids of sea-buckthorn and preparation method of composition | |
| CN107343925B (en) | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof | |
| CN105126034A (en) | Pharmaceutical preparation for treating coronary heart disease | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN101417075B (en) | Traditional Chinese medicine for treating respiratory system disease | |
| CN1970050A (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN103381260A (en) | Application of traditional Chinese medicinal composition in treating coronary heart disease | |
| CN103055122A (en) | Medicine for preventing restenosis after intracoronary stent implantation and preparation method thereof | |
| CN100384439C (en) | Medicinal composition for treating and/or preventing heart brnin blood vessel disease and its preparation method | |
| CN107468917B (en) | Traditional Chinese medicine composition for treating coronary heart disease by reducing phlegm and detoxifying and application thereof | |
| CN104189288B (en) | A kind of Chinese medicine composition for treating myocardial infarction and its application | |
| CN102416036B (en) | Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof | |
| CN104208571A (en) | Traditional Chinese medicinal composition for treating cardiovascular stenosis | |
| CN102641480A (en) | Traditional Chinese medicine composite used for treating microcirculation disturbance and preparation method thereof | |
| CN104435927B (en) | It is a kind of to treat cardiovascular narrow Chinese medicine composition and preparation method thereof | |
| CN103381261A (en) | Application of traditional Chinese medicinal composition in treating myocardial ischemia disease | |
| CN103316287A (en) | Application of traditional Chinese medicinal composition in preparation of treatment stent post-operation angiogenesis promoting medicines | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130703 Termination date: 20131209 |